AbbVie Inc (ABBV)vsForian Inc (FORA)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
FORA
Forian Inc
$2.16
+0.23%
HEALTHCARE · Cap: $67.33M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 202036% more annual revenue ($61.16B vs $30.26M). ABBV leads profitability with a 6.9% profit margin vs -9.5%. ABBV appears more attractively valued with a PEG of 0.48. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
FORA
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Intrinsic value data unavailable for FORA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 37.0% year-over-year
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -9.6% — below average capital efficiency
Earnings declined 89.1%
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : FORA
The strongest argument for FORA centers on Revenue Growth, PEG Ratio, Price/Book. Revenue growth of 37.0% demonstrates continued momentum. PEG of 0.94 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : FORA
The primary concerns for FORA are Market Cap, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ABBV profiles as a value stock while FORA is a hypergrowth play — different risk/reward profiles.
FORA carries more volatility with a beta of 0.99 — expect wider price swings.
FORA is growing revenue faster at 37.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 39/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Forian Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Forian Inc. provides a suite of software solutions, data management capabilities, proprietary data, and predictive analytics to optimize and measure operational, clinical, and financial performance for clients in the health and cannabis industries, as well as dispensaries. , cannabis growers, manufacturers, and distributors. The company is headquartered in Newtown, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?